PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.09%
Both companies show declining cash positions (-24.09% vs AGEN's -22.62%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-24.09%
Similar yoy growth to AGEN's -22.62%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.04%
Similar yoy growth to AGEN's -19.51%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-17.11%
Below half AGEN's 29.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.78%
Below half of AGEN's 8.16%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
≥ 1.5x AGEN's -11.00%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
86.42%
Less than half of AGEN's -34.93%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -0.70%. David Dodd sees stronger subscription/prepayment demand.
-55.20%
Less than half of AGEN's 40.00%. David Dodd sees fewer expansions in other current obligations.
21.67%
Above 1.5x AGEN's 5.40%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.67%
Above 1.5x AGEN's 9.08%. Michael Burry sees a potential leverage warning sign.
0.96%
Above 1.5x AGEN's 0.23%. Michael Burry suspects heavy new equity expansion or dilution.
-5.35%
1.25-1.5x AGEN's -4.86%. Bruce Berkowitz notes stronger reinvestment strategy.
-15.38%
Less than half of AGEN's 5.94%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Below half AGEN's -224.66%. Michael Burry sees potential underperformance in building shareholder capital.
-19.98%
≥ 1.5x AGEN's -11.00%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AGEN's 3.38%. David Dodd sees less overall debt expansion vs. competitor.
23.76%
Less than half of AGEN's 3134.66%. David Dodd sees better deleveraging or stronger cash buildup than competitor.